These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23901094)

  • 21. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
    Zuckerman RA; Lucchetti A; Whittington WL; Sánchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
    AIDS; 2009 Feb; 23(4):479-83. PubMed ID: 19169140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy.
    Tobian AA; Grabowski MK; Serwadda D; Newell K; Ssebbowa P; Franco V; Nalugoda F; Wawer MJ; Gray RH; Quinn TC; Reynolds SJ;
    J Infect Dis; 2013 Sep; 208(5):839-46. PubMed ID: 23812240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
    Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
    Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
    Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
    Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.
    Tanton C; Weiss HA; Rusizoka M; Legoff J; Changalucha J; Baisley K; Mugeye K; Everett D; Belec L; Clayton TC; Ross DA; Hayes RJ; Watson-Jones D
    J Infect Dis; 2010 May; 201(9):1285-97. PubMed ID: 20235836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya.
    Mugo N; Dadabhai SS; Bunnell R; Williamson J; Bennett E; Baya I; Akinyi N; Mohamed I; Kaiser R
    Sex Transm Dis; 2011 Nov; 38(11):1059-66. PubMed ID: 21992985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
    Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
    Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
    Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
    Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study.
    Brown EL; Wald A; Hughes JP; Morrow RA; Krantz E; Mayer K; Buchbinder S; Koblin B; Celum C
    Am J Epidemiol; 2006 Oct; 164(8):733-41. PubMed ID: 16896053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial.
    Barnabas RV; Baeten JM; Lingappa JR; Thomas KK; Hughes JP; Mugo NR; Delany-Moretlwe S; Gray G; Rees H; Mujugira A; Ronald A; Stevens W; Kapiga S; Wald A; Celum C;
    J Infect Dis; 2016 Feb; 213(4):551-5. PubMed ID: 26142452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
    Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
    N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.
    Mayaud P; Legoff J; Weiss HA; Grésenguet G; Nzambi K; Bouhlal H; Frost E; Pépin J; Malkin JE; Hayes RJ; Mabey DC; Bélec L;
    J Infect Dis; 2009 Jul; 200(2):216-26. PubMed ID: 19530940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
    Lingappa JR; Baeten JM; Wald A; Hughes JP; Thomas KK; Mujugira A; Mugo N; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Magaret AS; Wang RS; Kidoguchi L; Barnes L; Ridzon R; Corey L; Celum C;
    Lancet; 2010 Mar; 375(9717):824-33. PubMed ID: 20153888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
    McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
    Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
    PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressive valacyclovir therapy: impact on the population spread of HSV-2 infection.
    Williams JR; Jordan JC; Davis EA; Garnett GP
    Sex Transm Dis; 2007 Mar; 34(3):123-31. PubMed ID: 17325600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
    Fuchs J; Celum C; Wang J; Hughes J; Sanchez J; Cowan F; Reid S; Delany-Moretlwe S; Corey L; Wald A;
    J Infect Dis; 2010 Apr; 201(8):1164-8. PubMed ID: 20214474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incident HSV-2 infections are common among HIV-1-discordant couples.
    Muiru AN; Guthrie BL; Bosire R; Merkel M; Liu AY; Choi RY; Lohman-Payne B; Gatuguta A; Mackelprang RD; Kiarie JN; Farquhar C
    J Infect Dis; 2013 Oct; 208(7):1093-101. PubMed ID: 23840044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
    Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
    J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.